Aerie Pharma (AERI) PT Lowered to $24 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 4, 2021 4:01 PM EDTSecond Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020
Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020
Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Quarter of 2021
Conference Call and Webcast Today, August 4th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with... More
